Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Meloxicam

Meloxicam
Contact us for more batch information
Select Batch
Purity:99.89%
Resource Download

Meloxicam

Catalog No. T0826Cas No. 71125-38-7
Meloxicam (Metacam) is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of meloxicam is as a Cyclooxygenase Inhibitor. The chemical classification of meloxicam is Nonsteroidal Anti-inflammatory Compounds.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
100 mg$33In Stock
200 mg$45In Stock
500 mg$83In Stock
1 mL x 10 mM (in DMSO)$37In Stock
Bulk & Custom
Add to Cart

Related Compound Libraries of "Meloxicam"

Product Introduction

Bioactivity
Description
Meloxicam (Metacam) is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of meloxicam is as a Cyclooxygenase Inhibitor. The chemical classification of meloxicam is Nonsteroidal Anti-inflammatory Compounds.
Targets&IC50
COX-2:0.49 µM, COX-1:36.6 µM
In vitro
In horses, administration of Meloxicam significantly reduced lameness at both 8 and 24 hours post-injection and showed a tendency to decrease exudation. Compared to placebo, Meloxicam markedly inhibited the release of prostaglandin E2 and substance P in the synovial fluid 8 hours post-injection and reduced bradykinin release at 24 hours. Additionally, Meloxicam decreased average matrix metalloproteinase activity in the equine system at both 8 and 24 hours post-administration. Horses treated with Meloxicam or phenylbutazone showed improved postoperative pain and clinical outcomes compared to those treated with saline solution (SS). Meloxicam also induced a substantial infiltration of neutrophils in ischemic lesion tissues in horses. In dogs, Meloxicam significantly reduced concentrations of prostaglandin E2 in the blood and synovial fluid on days 7 and 21 post-administration, with no significant effect on thromboxane B2 (TXB2) levels in the blood or prostaglandin E2 (PGE2) concentrations in the gastric mucosa. Furthermore, Meloxicam inhibited tumor growth and pulmonary metastasis of LM-8 cells in mice.
In vivo
Meloxicam induces apoptosis in MG-63 cell cultures, concurrently upregulating both Bax mRNA and protein levels. It significantly reduces colony size in HCA-7 and Moser-S cells. While it markedly inhibits colony formation and tumor growth in HCA-7 cells, Meloxicam shows no effect on the growth of COX-2 negative HCT-116 cells. Furthermore, Meloxicam suppresses PGE(2) production, proliferation, and invasiveness, particularly in MG-63 cells expressing relatively higher levels of COX-2.
AliasMovalis, Mobic, Metacam
Chemical Properties
Molecular Weight351.4
FormulaC14H13N3O4S2
Cas No.71125-38-7
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 12 mg/mL (34.15 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.8458 mL14.2288 mL28.4576 mL142.2880 mL
5 mM0.5692 mL2.8458 mL5.6915 mL28.4576 mL
10 mM0.2846 mL1.4229 mL2.8458 mL14.2288 mL
20 mM0.1423 mL0.7114 mL1.4229 mL7.1144 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Meloxicam | purchase Meloxicam | Meloxicam cost | order Meloxicam | Meloxicam chemical structure | Meloxicam in vivo | Meloxicam in vitro | Meloxicam formula | Meloxicam molecular weight